DBV Technologies (DBVT) Return on Capital Employed (2020 - 2026)
DBV Technologies (DBVT) reported Return on Capital Employed of 84.91% for Q1 2026, up 56177.0% year-over-year from N/an in Q1 2025, and up 34.11% quarter-over-quarter from 128.87% in Q4 2025.
DBV Technologies (DBVT) Return on Capital Employed (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of Return on Capital Employed data on file, last reported at 84.91% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 84.91%, up 56177.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 84.91% (up 56177.0% YoY), and the FY2025 annual result was 160.4%, down 3529.0% from the prior year.
- Return on Capital Employed advanced to 84.91% in Q1 2026 per DBVT's latest filing, from 128.87% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 30.27% in Q3 2022 and troughed at 646.68% in Q1 2025.
- A 5-year average of 131.18% and a median of 80.8% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed tumbled 58592 bps in 2025, then surged 56177 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 44.37% in 2022, then retreated by 16 bps to 51.28% in 2023, then slumped by 371 bps to 241.78% in 2024, then jumped by 47 bps to 128.87% in 2025, then surged by 34 bps to 84.91% in 2026.
- Business Quant data shows DBVT's Return on Capital Employed at 84.91% in Q1 2026, 128.87% in Q4 2025, and 162.43% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -84.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.91% |
| Dec 31, 2025 | -128.87% |
| Sep 30, 2025 | -162.43% |
| Jun 30, 2025 | -256.25% |
| Mar 31, 2025 | -646.68% |
| Dec 31, 2024 | -241.78% |
| Sep 30, 2024 | -143.93% |
| Jun 30, 2024 | -90.19% |
| Mar 31, 2024 | -60.76% |
| Dec 31, 2023 | -51.28% |
| Sep 30, 2023 | -59.54% |
| Jun 30, 2023 | -53.31% |
| Mar 31, 2023 | -48.82% |
| Dec 31, 2022 | -44.37% |
| Sep 30, 2022 | -30.27% |
| Jun 30, 2022 | -45.91% |
| Mar 31, 2022 | -80.80% |
| Dec 31, 2021 | -77.39% |
| Sep 30, 2021 | -82.46% |
| Jun 30, 2021 | -75.85% |